With products for urological and colon cancers already on the market, MDxHealth and Exact Sciences (NASDAQ: EXAS) have already demonstrated their respective expertise in the development of epigenetic molecular diagnostics. The new five year collaboration announced with Exact will enable MDxHealth to leverage its epigenetic expertise outside its core urological focus, as well as build on a decade long relationship with Exact. Exact's acquisition of key MDxH patents related to Exact's Cologuard co ....
28 Apr 2017
Exact Sciences collaboration
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Exact Sciences collaboration
MDxHealth S.A. (0O8G:LON) | 0 0 0.3% | Mkt Cap: 168.5m
- Published:
28 Apr 2017 -
Author:
Chris Redhead -
Pages:
5
With products for urological and colon cancers already on the market, MDxHealth and Exact Sciences (NASDAQ: EXAS) have already demonstrated their respective expertise in the development of epigenetic molecular diagnostics. The new five year collaboration announced with Exact will enable MDxHealth to leverage its epigenetic expertise outside its core urological focus, as well as build on a decade long relationship with Exact. Exact's acquisition of key MDxH patents related to Exact's Cologuard co ....